“DT56a decreased menopausal symptoms significantly and in the same degree as HT.”

Efficacy and safety of DT56a compared to hormone therapy in Greek post-
menopausal women.

Results:

Patients receiving HT and DT56a showed a significant and independent decrease in
menopausal symptoms (mean difference in Kupperman score, DT56a group: -3.98, HT group
-5.601, no treatment group +1.76, p-value <0.001). Lumbar spine BMD T-score was
significantly lower in women receiving no treatment, as opposed to the two treatment arms
which showed no significant change (No treatment, baseline: -0.60, final: -0.85, p=0.001; HT,
baseline: -84, final -0.99, p=0.79; DT56a, baseline -0.51, final: -0.76, p=0.75). No differences
in femoral bone density, ET or mammography classification were detected in any of the
treatment arms. Likewise, serum lipids or lipoproteins did not differ between the three

Contact Us

info@se-curepharma.com

Se-cure Pharmaceuticals

1 Ha'arava st, Airport City

Israel